Raptor Pharmaceutical Corp (NASDAQ:RPTP)

CAPS Rating: 2 out of 5

Results 1 - 2 of 2

Recs

0
Member Avatar michaeltbryant (< 20) Submitted: 10/28/2012 1:13:52 AM : Outperform Start Price: $4.64 RPTP Score: +56.21

strong pipeline

Recs

2
Member Avatar bassman87 (< 20) Submitted: 11/22/2010 1:52:32 PM : Outperform Start Price: $3.59 RPTP Score: +87.85

Has a solid pipeline of products that should be advancing into phase 3 stage of FDA approval and beyond through the next 12 to 36 months.

Most notable of all its products currently in phase 2 stage of development, is the drug Convivia. It is the only known drug currently in development and existence, that treats the "Asian Flush" symptoms associated with the consumption of alcohol by those who have the ALDH2 deficiency. There is a potentially huge market for this, as 40-50% of the East Asian populations suffers from this disorder alone. Chances are you know someone who suffers from this, evident by the appearence of red flush or blotchy areas to the face and neck area, and sometimes all over the body.

Demand for this product could be very high as there are many medical(cancer risk) and social(public appearence) implications to having this disorder.

Results 1 - 2 of 2

Featured Broker Partners


Advertisement